WASHINGTON — Kitchen-table America does not need another lecture about drug prices. It needs a President who finishes the job. On Wednesday, September 30, coverage confirms the Trump Administration finalized the Global Benchmark for Efficient Drug Pricing — GLOBE — the Medicare Part B payment model built to carry Most Favored Nation pricing into the clinic where cancer therapies, autoimmune drugs, and other infused medicines hit seniors hardest.
CMS describes GLOBE as a mandatory model that assesses a rebate for certain Original Medicare Part B drugs when U.S. prices exceed those paid in economically comparable countries. The point is America First fairness: stop Americans from paying a premium the rest of the developed world refuses. CMS expects the model to reduce out-of-pocket drug costs for people with Medicare and produce savings to Medicare while preserving or enhancing quality of care.
The design targets clinic-administered Part B medicines — not the pharmacy counter Part D lane. CMS focuses on high-spend therapeutic classes such as oncology, rheumatology, immunology, ophthalmology, and endocrinology, where annual Original Medicare spending can top $100 million and access barriers from high costs leave patients choosing between treatment and the rest of life. Rebates paid by manufacturers continue to the Medicare Supplementary Medical Insurance Trust Fund under the model framework CMS published.
Bloomberg Law notes a separate Part D model is still under White House review — so this piece stays disciplined. Wednesday’s win is Part B GLOBE finalized. No invented savings scoreboard for GLOBE itself. The kitchen-table promise CMS states is enough: lower out-of-pocket costs so seniors can afford and continue necessary Part B medications.
Pharmaceutical lobbyists have already telegraphed legal challenges — the same resistance Trump faced when he first pushed Most Favored Nation thinking. Patriots know the contrast. One side protects global sticky prices and calls it “innovation.” President Trump’s CMS puts international benchmarks on the table and tells manufacturers Americans will not keep funding everyone else’s discount.
Race to the Mid-terms healthcare politics is blunt. Voters remember who talked about drug prices and who built the model. GLOBE is the Part B chapter of Trump’s Most Favored Nation fight — clinic drugs, manufacturer rebates, Medicare sustainability, and a White House that treats seniors like citizens, not captive customers. That is Golden Age healthcare done the America First way.
